These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38604296)

  • 1. Differential Effects of Genetic Polymorphism on Comorbid Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Seko Y; Yamaguchi K; Shima T; Iwaki M; Takahashi H; Kawanaka M; Tanaka S; Mitsumoto Y; Yoneda M; Nakajima A; Okanoue T; Itoh Y
    Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1436-1443.e4. PubMed ID: 38604296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of
    Elmansoury N; Megahed AA; Kamal A; El-Nikhely N; Labane M; Abdelmageed M; Daly AK; Wahid A
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population.
    Rashu EB; Werge MP; Hetland LE; Thing M; Nabilou P; Kimer N; Junker AE; Jensen AH; Nordestgaard BG; Stender S; Gluud LL
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102389. PubMed ID: 38830575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Genetic Variation in PNPLA3, TM6SF2 and HSD17B13 have a Role in the Development or Prognosis of Hepatocellular Carcinoma in Turkish Patients with Hepatitis B?
    Demirtas CO; Eren F; Yilmaz D; Ozdogan OC; Gunduz F
    J Gastrointestin Liver Dis; 2024 Jun; 33(2):203-211. PubMed ID: 38944871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PNPLA3 risk allele is associated with risk of hepatocellular carcinoma but not decompensation in compensated cirrhosis.
    Urias E; Tedesco NR; Burkholder DA; Moran IJ; Miller MJ; Jasty VSJ; Patil S; Zoellner S; Wijarnpreecha K; Chen VL
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38780253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
    Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
    Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
    Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
    Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct Gut Microbial Signature and Host Genetic Variants in Association with Liver Fibrosis Severity in Patients with MASLD.
    Satthawiwat N; Jinato T; Sutheeworapong S; Tanpowpong N; Chuaypen N; Tangkijvanich P
    Nutrients; 2024 Jun; 16(12):. PubMed ID: 38931155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriasis and steatotic liver disease: Are PNPLA3 and TM6SF2 polymorphisms suitable for the hepato-dermal axis hypothesis?
    Agoglia L; Cardoso AC; Barbosa L; Victer CSXL; Carneiro S; de França PHC; Chindamo MC; Villela-Nogueira CA
    Ann Hepatol; 2024; 29(4):101477. PubMed ID: 38360269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver-Related Events in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Seko Y; Yamaguchi K; Shima T; Iwaki M; Takahashi H; Kawanaka M; Tanaka S; Mitsumoto Y; Yoneda M; Nakajima A; Okanoue T; Itoh Y
    Liver Int; 2024 Oct; ():. PubMed ID: 39373247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interplay between Helicobacter pylori infection and rs738409 PNPLA3 in metabolic dysfunction-associated steatotic liver disease.
    Maiorana F; Neschuk M; Caronia MV; Elizondo K; Robledo ML; Schneider A; Veron G; Zapata PD; Barreyro FJ
    PLoS One; 2024; 19(9):e0310361. PubMed ID: 39312529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort.
    Chen VL; Du X; Oliveri A; Chen Y; Kuppa A; Halligan BD; Province MA; Speliotes EK
    J Hepatol; 2024 Sep; 81(3):379-388. PubMed ID: 38582304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
    Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
    Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus.
    Lavrado NC; Salles GF; Cardoso CRL; de França PHC; Melo MFDGG; Leite NC; Villela-Nogueira CA
    Liver Int; 2024 Apr; 44(4):1042-1050. PubMed ID: 38293718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Fibrosis Assessed Via Noninvasive Tests Is Associated With Incident Heart Failure in a General Population Cohort.
    Hydes TJ; Kennedy OJ; Glyn-Owen K; Buchanan R; Parkes J; Cuthbertson DJ; Roderick P; Byrne CD
    Clin Gastroenterol Hepatol; 2024 Aug; 22(8):1657-1667. PubMed ID: 38723982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease in children.
    Lee KJ; Moon JS; Lim JG; Huh H; Ahn JE; Kim L; Kim NY; Ko JS
    J Gastroenterol Hepatol; 2024 Jun; 39(6):1172-1182. PubMed ID: 38418429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.
    Bridi L; Agrawal S; Tesfai K; Madamba E; Bettencourt R; Richards LM; Khera AV; Loomba R; Ajmera V
    Aliment Pharmacol Ther; 2024 Aug; 60(3):369-377. PubMed ID: 38825972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
    Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
    Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis.
    Beaudoin JJ; Liang T; Tang Q; Banini BA; Shah VH; Sanyal AJ; Chalasani NP; Gawrieh S
    Alcohol Clin Exp Res; 2021 Apr; 45(4):709-719. PubMed ID: 33616244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.